First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors

By sjmartinez • February 19, 2025

Naing A, McKean M, Rosen LS, Sommerhalder D, Shaik NM, Wang IM, Le Corre C, Kern KA, Mishra NH, Pal SK. First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors. ESMO Open. 2025 Feb 17;10(3):104291. doi: 10.1016/j.esmoop.2025.104291. Epub ahead of print. PMID: 39965362.

Tags: advanced or metastatic solid tumors, anti-drug antibodies, anti-PD-1–IL-15 fusion, antibody–cytokine fusion molecule, Hematology/Oncology, phase I study, Publications

Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT

Samorodnitsky S, Campbell K, Little A, Ling W, Zhao N, Chen YC, Wu MC. Detecting clinically relevant topological structures in multiplexed spatial proteomics using TopKAT.[...]

Mitochondrial DNA Fragment Dynamics in Acute and Chronic Human Immunodeficiency Virus: Insights From Human and Nonhuman Primate Models

Sun J, Nidadavolu LS, Hsu HY, Rajagopal RG, Astemborski J, Wu Y, Jiang Y, Sacha JB, Kievit P, Jamieson BD, Roberts CT, Kirk GD, Brown[...]

CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis

Park D, Varda M, Yeremian S, Hwang A, Huang C. CDK4/6 Inhibition in the Management of Metastatic HR+/HER2+ Breast Cancer: Systematic Review and Meta-analysis. Target[...]